IRIS
GOZZETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.523
EU - Europa 8.460
AS - Asia 1.668
SA - Sud America 38
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 21.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.474
GB - Regno Unito 2.192
IE - Irlanda 1.685
CN - Cina 1.020
IT - Italia 977
UA - Ucraina 839
SE - Svezia 775
RU - Federazione Russa 742
FR - Francia 512
SG - Singapore 373
DE - Germania 355
FI - Finlandia 214
VN - Vietnam 93
TR - Turchia 62
CA - Canada 38
BE - Belgio 32
BR - Brasile 24
NL - Olanda 24
IN - India 23
CZ - Repubblica Ceca 20
JP - Giappone 17
ES - Italia 13
HK - Hong Kong 13
IR - Iran 13
CI - Costa d'Avorio 12
RS - Serbia 10
AU - Australia 9
TW - Taiwan 9
CL - Cile 8
MX - Messico 8
PL - Polonia 8
CH - Svizzera 7
EU - Europa 7
EE - Estonia 6
LT - Lituania 5
MY - Malesia 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
AT - Austria 4
DK - Danimarca 4
ID - Indonesia 4
KG - Kirghizistan 4
LU - Lussemburgo 4
LV - Lettonia 4
MA - Marocco 4
RO - Romania 4
SA - Arabia Saudita 4
BD - Bangladesh 3
EG - Egitto 3
GR - Grecia 3
JO - Giordania 3
LA - Repubblica Popolare Democratica del Laos 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
HR - Croazia 2
KZ - Kazakistan 2
PE - Perù 2
PT - Portogallo 2
SM - San Marino 2
UZ - Uzbekistan 2
A1 - Anonimo 1
AR - Argentina 1
BY - Bielorussia 1
EC - Ecuador 1
IL - Israele 1
IS - Islanda 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
Totale 21.728
Salva come PNG Salva come JPEG
Città #
Fairfield 2.035
Southend 1.986
Dublin 1.664
Woodbridge 989
Ashburn 946
Chandler 813
Seattle 772
Houston 766
Wilmington 766
Jacksonville 730
Cambridge 638
Ann Arbor 409
Princeton 372
Santa Clara 337
Siena 317
Singapore 271
Nanjing 244
Beijing 223
San Mateo 133
Boardman 109
Helsinki 103
San Diego 101
Dong Ket 88
Moscow 78
Nanchang 77
Dearborn 63
Shanghai 63
Rome 59
Florence 56
London 54
Shenyang 54
Menlo Park 50
Hebei 48
Izmir 45
New York 42
Tianjin 41
Milan 39
Jiaxing 38
Kunming 35
Brussels 32
San Francisco 30
Norwalk 25
Changsha 22
Toronto 21
Kilburn 20
Lappeenranta 18
Zhengzhou 18
Brno 17
Munich 17
Ningbo 17
Jinan 16
Los Angeles 16
Turin 15
Fremont 14
Guangzhou 14
Washington 14
Abidjan 12
Redwood City 12
Taizhou 12
Bologna 11
Changchun 10
Frankfurt am Main 10
Haikou 10
Hong Kong 10
Hounslow 10
Kocaeli 10
Pisa 10
Tokyo 10
Belgrade 9
Düsseldorf 9
Falls Church 9
Hefei 9
Amsterdam 8
Chiswick 8
Dallas 8
Lanzhou 8
Leawood 8
Hangzhou 7
Málaga 7
Naples 7
Poggibonsi 7
San Giuliano Terme 7
Taipei 7
Colle Di Val D'elsa 6
Columbus 6
Fuzhou 6
Livorno 6
Mexico City 6
Tallinn 6
Zanjan 6
Bangkok 5
Bratislava 5
Council Bluffs 5
Hyderabad 5
New Bedfont 5
Palermo 5
Philadelphia 5
Phoenix 5
Sacramento 5
Stockholm 5
Totale 16.317
Salva come PNG Salva come JPEG
Nome #
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 210
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 208
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 206
Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. 205
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 205
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 202
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 201
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 199
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 199
Second generation proteasome inhibitors in multiple myeloma 197
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis 184
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 178
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 175
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 173
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 173
Central nervous system multiple myeloma 169
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 163
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients 163
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 159
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 159
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 159
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 158
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma. 157
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 155
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 153
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 153
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 152
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 151
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 151
Evolving treatments in multiple myeloma patients with renal failure 148
Predicting the clinical course of Hodgkin lymphoma 147
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 146
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice 143
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 143
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 142
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors 141
Treatment of smoldering multiple myeloma 141
Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy 140
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 138
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 136
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 135
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 135
Hyperlipidemia in a myeloma patient after bortezomib treatment 134
Unusual localizations of plasmacytoma 134
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 133
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 132
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 132
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study 132
Extramedullary myeloma relapses 131
Adult lymphoblastic lymphoma: Clinical features and prognostic factors in 53 patients 131
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 130
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 128
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 128
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 127
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 127
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 126
FLT3 inhibitors in the management of acute myeloid leukemia 126
Central Nervous System Multiple Myeloma 125
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients 123
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up 122
Central nervous system multiple myeloma: a different cytogenetic profile 121
The effects of zoledronic acid on serum lipids in multiple myeloma patients 120
Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues 119
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 118
Insights into JAK2-V617F mutation in CML. 118
An unusual presentation of chronic B-cell lymphocytic leukaemia 118
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 118
Trisomy 13 in a patient with idiopathic myelofibrosis 117
Outcome and toxicity in the modern era of new drugs for multiple myeloma: A reappraisal for comparison with future investigational trials 116
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 116
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 115
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 115
Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports 115
Novel agents in CNS myeloma treatment 115
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma 114
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 114
Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay 114
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study 114
Efficacy of bortezomib, lenalidomide and dexamethasone(VRD) in secondary plasma cell leukaemia 113
Reply to “Rituximab activity in CD20-positive multiple myeloma” 112
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: Pathogenetic and prognostic implications 112
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia 111
Daratumumab efficacy in extramedullary orbital myeloma 111
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma 111
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 111
Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission 110
Physicians and end-of-life issues 110
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region 110
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 109
Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders. 109
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia 108
Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization 108
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 108
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 108
IgM myeloma: A multicenter retrospective study of 134 patients 107
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 107
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: Thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin 106
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 106
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 105
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study 103
Totale 13.765
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.124
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.124
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.015 0 0 0 0 324 402 471 597 408 437 129 247
2020/20214.053 159 392 317 631 247 427 139 547 279 375 257 283
2021/20222.442 160 250 174 179 93 100 125 91 126 285 276 583
2022/20233.273 240 227 440 475 281 677 87 248 298 46 188 66
2023/20242.461 105 57 226 133 68 612 849 48 20 69 39 235
2024/20251.822 173 295 556 321 477 0 0 0 0 0 0 0
Totale 22.263